Company intelligence / Profile preview

Enumera Molecular

Ann Arbor, Michigan, United Statesenumeramolecular.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Enumera Molecular develops the EnumeraPlex™ platform to simplify and reduce the cost of complex clinical genomic/molecular diagnostic testing. Their approach enables rapid liquid biopsy and high-dimensional assays with a single workflow suitable for any lab size. The company’s pipeline includes multiple test panels targeting oncology, reproductive health, transplant medicine, pharmacogenomics, and infectious diseases. No published clinical results yet.

Therapeutic areas: OncologyWomen's HealthImmunologyOtherInfectious Diseases
Modalities: Device (diagnostic platform)Liquid biopsy technologyHigh-dimensional assay platform
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Enumera Molecular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enumera Molecular.

Explore the full profile